Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.

BMC cancer - 14 Mar 2014

Chen Yu-Wen, Hsiao Pi-Jung, Weng Ching-Chieh, Kuo Kung-Kai, Kuo Tzu-Lei, Wu Deng-Chyang, Hung Wen-Chun, Cheng Kuang-Hung

Abstract excerpt

BACKGROUND: SMAD4 is a gastrointestinal malignancy-specific tumor suppressor gene found mutated in one third of colorectal cancer specimens and half of pancreatic tumors. SMAD4 inactivation by allelic deletion or intragenic mutation mainly occurs in the late stage of human pancreatic ductal adenocarcinoma (PDAC). Various studies have proposed potential SMAD4-mediated anti-tumor effects in human malignancy;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Gene Knockdown Techniques

Share to HEK293 Cells

Share to Mice, SCID

Share to Pancreatic Neoplasms

Share to Smad4 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 24625091
DOI: 10.1186/1471-2407-14-181
PMCID: PMC4007528

Genes

SMAD4
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.PMID 24625091Read ↗

New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical SignificanceSemantic proximity Read ↗

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.Semantic proximity Read ↗

Insights Into SMAD4 Loss in Pancreatic Cancer From Inducible Restoration of TGF-β Signaling.Semantic proximity Read ↗

Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

The role of TGF-β/SMAD4 signaling in cancer.Semantic proximity Read ↗

Smad4 deficiency substitutes Cdkn2b but not Cdkn2a downregulation in pancreatic cancer following induction of genetic events in adult mice.Semantic proximity Read ↗

Two sides of the story? Smad4 loss in pancreatic cancer versus head‐and‐neck cancerSemantic proximity Read ↗

Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells.Semantic proximity Read ↗

Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic NeoplasiaSemantic proximity Read ↗

Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.